Chiasma Inc. (NASDAQ:CHMA) shares traded down 3.5% during trading on Friday . The stock traded as low as $2.72 and last traded at $2.74, with a volume of 55,732 shares changing hands. The stock had previously closed at $2.84.

Several research analysts have commented on the stock. Zacks Investment Research downgraded shares of Chiasma from a “hold” rating to a “sell” rating in a report on Monday, April 25th. Cowen and Company reissued a “hold” rating on shares of Chiasma in a report on Friday, May 13th. William Blair downgraded shares of Chiasma from an “outperform” rating to a “market perform” rating in a report on Monday, April 18th. Barclays PLC reaffirmed a “buy” rating and set a $40.00 price objective on shares of Chiasma in a report on Thursday, March 31st. Finally, Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $9.00 price objective (down from $43.00) on shares of Chiasma in a report on Monday, April 18th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $19.70.

The company’s market capitalization is $66.58 million. The stock has a 50 day moving average price of $2.86 and a 200-day moving average price of $6.94.

Chiasma (NASDAQ:CHMA) last announced its earnings results on Wednesday, May 11th. The company reported ($0.71) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.08. On average, analysts predict that Chiasma Inc. will post ($2.66) earnings per share for the current fiscal year.

Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.